Andrew A. Hindman - Nov 18, 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP, CHIEF FINANCIAL OFFICER
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Stock symbol
TBPH
Transactions as of
Nov 18, 2022
Transactions value $
-$988,110
Form type
4
Date filed
11/22/2022, 03:07 PM
Previous filing
Aug 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Sale -$716K -65K -13.69% $11.02 410K Nov 18, 2022 Direct F1, F2
transaction TBPH Ordinary Shares Tax liability -$272K -25.1K -6.11% $10.85 385K Nov 20, 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades at prices from $10.7891 to $11.2750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
F2 Includes 1,264 shares acquired under the Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan on November 15, 2022.
F3 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.